Mike Romanos Appointed as CSO of Crescendo Biologics
Mike Romanos has been appointed Chief Scientific Officer of Crescendo Biologics and joins the Board as a Director. Dr Romanos will take leadership of the company and its proprietary antibody fragment technologies following a £4.5 million seed fundraising round led by Sofinnova Partners.
Dr Romanos has more than 23 years biotech and pharma industry experience and within the last 10 years has held senior global positions leading major parts of GlaxoSmithKline Discovery. In his most recent role as VP, Discovery Technology, at GSK, he had global responsibility for genomic and cellular platforms, and a central involvement in target and biomarker selection across all of GSK’s therapeutic areas. Prior to that, as VP, Gene Expression and Protein Biochemistry, he had global responsibility for the generation of biologicals to support all of GSK’s Discovery activities, for use in screening, structural biology and as biopharmaceuticals. During this phase he established GSK’s advanced antibody lead discovery capability which was critical to generating the pipeline of in-house monoclonal antibodies.
“I am excited to be taking this role at Crescendo,” said Mike Romanos. “This new company has the components to build class-leading platforms in the field of next generation antibody therapeutics. With the funding in place, we are well-placed to develop our technology platforms and then, drawing on our insights in therapeutic target opportunities, begin applying them to in-house projects and future partnership programmes.”
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
